SEARCH
Subscribe
Track all markets on TradingView

4 Canadian Stocks with the Highest Return on Equity

Published:

Reading time: 4 min.

The Canadian stocks on our list have generated superior Return on Equity (ROE) of more than 100%

SmallCapPower | October 2, 2017: Today we have identified four Canadian stocks with high Return on Equity (ROE) ratios of more than 100%. ROE is a measure of profitability of a business in relation to its shareholders’ equity. ROE is a key metric for gauging the success of a company, as it measures of how well it uses investments to generate earnings growth. A high ROE also signifies strong management, as it shows they have allocated shareholders’ capital to high-return projects.

Greenfields Petroleum Corp. (TSXV: GNF)

Greenfields Petroleum Corp. is a junior oil and natural gas exploration and development corporation focused on the development and production of proven oil and gas reserves principally in the Republic of Azerbaijan.

  • TTM Revenues: $30.7 million
  • MarketCap: $28.8 million
  • Return on Equity: 135.8%
  • Price ChgPct YTD: -44.8%

Inter Rock Minerals Inc. (TSXV: IRO)

Inter Rock Minerals Inc explores and mines for mineral reserves in North America and Europe.The Company is engaged in the production and marketing of high purity dolomite throughout the U.S.

  • TTM Revenues: $45.8 million
  • MarketCap: $5.6 million
  • Return on Equity: 124.3%
  • Price Chg Pct YTD:66.7%

 Paramount Resources Ltd. (TSX: POU)

Paramount Resources Ltd. explores and develops unconventional and conventional petroleum and natural gas prospects, including long-term unconventional exploration and pre-development projects, and holds a portfolio of investments in other entities. The Company operates primarily in western Canada.

  • TTM Revenues: $214.1 million
  • MarketCap: $3.2billion
  • Return on Equity: 118.6%
  • Price Chg Pct YTD: 46.1%

Medicure Inc. (TSXV: MPH)

Medicure Inc. is a cardiovascular drug discovery and development company focused on developing therapeutics for unmet needs in the field of cardiovascular medicine.  The Company’s current focus is on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke.

  • TTM Revenues: $53.1 million
  • MarketCap: $125.2 million
  • Return on Equity: 113.7%
  • Price Chg Pct YTD: -22.2%

 

Disclosure: Neither the author nor any of the principals at SmallCapPower, or their family members, own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below:

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
test28872674
test28872674

Related articles

Recent articles

© SmallCapPower 2024